Prof Benjamin Besse speaks to ecancer about the results from the LATIFY trial evaluating a novel combination of an ATR inhibitor with durvalumab compared with standard chemotherapy in patients with advanced non-small cell lung cancer who had progressed after prior immunotherapy and platinum-based treatment.

The study found that the combination did not improve overall survival, progression-free survival, or response rates compared with docetaxel.

Despite this, the regimen showed a more favourable safety profile, with fewer high-grade treatment-related adverse events and lower discontinuation rates.

These findings highlight the ongoing challenges in developing effective post-immunotherapy treatment strategies in lung cancer, while also suggesting that targeting DNA damage response pathways may still warrant further investigation in selected settings.